English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Highlights From the ASGCT 25th Annual Meeting
Delivery of CRISPR/Cas9 mRNA LNPs to Repair a Small Deletion in FVIII Gene in Hemophilia A Mice
Presented by: Chun-Yu Chen, PhD, Fellow-PhD | Immunity & Immunotherapies, Seattle Children's Seattle, Washington, United States
Chun-Yu Chen1, Cai Xiaohe1, Carol Miao1,2
1Seattle Children’s Research Institute, Seattle, Washington
2Department of Pediatrics, University of Washington, Seattle, Washington
Key Data Points
- mRNA LNPs Target Both Hepatocytes and LSECs
- Cas9 and sgRNA LNPs Enable NSG HemA Mice to Regain Endogenous Plasma FVIII Activity
Various formulations of luciferase mRNA (Luc) encapsulated in MC3-based lipid nanoparticles (LNPs) were intravenously injected into mice. Luciferase expression was mainly detected in liver, with the strongest expression shown by LNP formulation 5. Liver immunostaining staining demonstrated that Dil-labeled LNP can successfully transfect both hepatocytes and endothelial cells in vivo.
Encapsulated Cas9 mRNA and single-guide RNA (sgRNA) LNPs were delivered into immunodeficient hemophilia A (NSG HA) mice intravenously. Stable expression of endogenous FVIII for up to 4 weeks was confirmed by aPTT assay and edited mutant FVIII was verified by DNA sequencing and online CRISPR analysis tools, respectively.
RELATED CONTENT
